Anti-Avelumab-PD-L1 antibody (STJA0032517)
SPECIFICATIONS
ClonalityMonoclonal
HostHumanized
ConjugationUnconjugated
IsotypeIgG1
General Information
| Short Description | Humanized monoclonal anti-Avelumab-PD-L1 for use in FUNC in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | FUNC |
| Host | Humanized |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Conjugation | Unconjugated |
| Purification | Affinity Purified |
| Formulation | 0.01M PBS, pH 7.2 |
| Storage Instruction | This solution is stable for at least 4 weeks when stored at 2-8°C. For long term storage aseptically aliquot and store at –80°C. Avoid repeated freeze/thaw cycles. |
Target Information
Additional Info
| Background | Avelumab biosimilar is a programmed death ligand-1 (PD-L1) blocking antibody and prevents its interaction with the inhibitory T-cell receptor, PD-1 (programmed cell death protein 1). Upon binding, avelumab promotes T-cell reactivation and restores T-cell-mediated immune response against tumor cells. Avelumab is also the only PD-L1 antibody so far to also induce antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing PD-L1. |
Information sourced from Uniprot.org